Liu, Chun-Yu <br/><br/>
Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.  [electronic resource] 

 -  Oncotarget  Feb 2016 
 - 9135-49 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.7035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Autoantigens<br/>Cell Line, Tumor<br/>Disease Models, Animal<br/>ErbB Receptors--antagonists & inhibitors<br/>Humans<br/>Lapatinib<br/>MCF-7 Cells<br/>Membrane Proteins--antagonists & inhibitors<br/>Mice<br/>Mice, Nude<br/>Promoter Regions, Genetic--drug effects<br/>Protein Kinase Inhibitors--pharmacology<br/>Protein Phosphatase 2--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Quinazolines--pharmacology<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Triple Negative Breast Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays